burden between 10 4 and 10 5 cells. 16,17 Similarly, although are found in the majority of patients with B lineage acute lym-PCR positivity often precedes clinical relapse, [7][8][9][13][14][15] bone marrow in cohorts of childhood, and adult ALL patients.
Introduction
Material and methods The clonally rearranged IgH gene can be used to follow minimal residual disease (MRD) in the majority of B lineage and
Patients a proportion of T lineage cases of acute lymphoblastic leukaemia (ALL). The majority of studies of MRD in ALL have
Twenty-one children (Ͻ15 years of age) and 33 adults, from concentrated on children alone [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] or on mixed populations this and other centres in the UK were studied (Table 1) . Sixof children and adults. [13] [14] [15] To date, there has been no systemteen children and 30 adults were studied as newly diagnosed atic comparison of the prognostic implication of MRD ALL, while the other patients (five children and three adults) between adult and childhood ALL, in a single study.
were initially studied in first or subsequent hematological With regards to the predictive value of positive and negative relapse. The majority of children received the UKALLX and tests, most studies have concluded that the elimination of UKALLXI protocols, while the majority of adults received the MRD, as reflected by PCR negativity (using tests with a sensi-UKALLXII protocol. Patients were classified as having ALL on tivity of 1:10 5 ), is a pre-requisite for long-term disease-free surthe basis of standard morphologic and immunophenotypic crivival, 16 although this equates to a total body leukaemic cell teria. 20 The different subgroups of patients, duration of followup, total number of samples tested and outcome are summar- Samples and PCR amplification of presentation Follow-up period material MRD was sought in 203 BM samples obtained from 3 weeks Mononuclear cell separation and DNA extraction from bone to 70.5 months from initial testing in adults (85 samples) and marrow, one testicular biopsy (patient C19) and one chloroma children (118 samples). An average of two samples in adults (patient C11) were carried out as previously described. 21 PCR (range 1-7) and six samples in children (range 1-10) were analysis, cloning and sequencing for FR1 and CDR3 analysis studied. were performed as described elsewhere.
13,19

Patient
Among remission patients, except for three adults (A3, A14 sequences were compared to published sequences of the V, and A29) who died at 14 months, 1 month and 17.5 months D and J segments. [22] [23] [24] [25] [26] [27] For inclusion in this study it was necespost-induction, respectively, of causes related to therapy in sary that patients entered clinical and morphological clinical remission, all patients have been followed for у24 remission and that samples were PCR positive for amplifimonths or have relapsed earlier. Relapsed patients had a cation of the ␤-actin control sequence. 28 shorter follow-up period than remission patients only among adults (Table 1) . With the exception of five patients, all children have relapsed after a long follow-up period or are in FR1 fingerprinting and ASO analysis for MRD second or later CR with a median follow-up over 42 months. investigation All follow-up samples were analysed using the FR1 primers in Relapse in adult and childhood patients combination with the JH primer (sensitivity у1:5 × 10
3 ). Patients who tested negative for MRD using this technique were subsequently analysed using an allele-specific oligonuAmong newly diagnosed patients, 12 of 30 adults and seven of 16 children relapsed between 3 and 39 months from prescleotide (ASO) primer, generated via the cloning of the rearranged PCR product/s identified on the presentation entation. Eight patients (three adults and five children) presented in first or subsequent relapse. With the exception of material as previously described. 19 Criteria for ASO tests were as follows: (1) primers showed no background signal on norone adult and one childhood ALL, all patients in this subgroup suffered further relapses. Two patients had CNS relapse (A32 mal bone marrow; (2) their size was у18 bp; (3) patients had monoclonal B cell disease; and (4) patients had been tested and C19), one had testicular relapse (C19), one patient had a chloroma (in third relapse, C11) while all other relapses were negative by the FR1 fingerprinting test. These criteria were fulfilled in 13 children and 19 adults and ASO tests were carried medullary. Relapses occurred more frequently among patients who had presented in (four of five children, 80% and two of out on follow-up specimens to estimate the level of MRD between 1:10 4 and 1:10 5 , as previously described. 19 Two chilthree adults, 66%) than in newly diagnosed patients (seven of 16 children, 43.7% and 12 of 30 adults, 40%). Eleven of 21 dren and three adults could not be tested by ASO for failing criteria (1) (C10, C17 and A2, A9, A14); two patients were not children (52%) were diagnosed to have pre-B ALL (Table 1) , while 30% among adults (10 of 33) were found to have the tested for failing criteria (2) (C5 and A17) and one child and three adults for failing criteria (3) (C2, A8, A17 and A30). In same phenotype. We observed that among children, a higher proportion of relapses occurred among pre-B ALL (eight of 11 three children (C13, C20 and C21) and seven adults (A7, A11, A22, A27-A29, A33) all samples were positive for fingerpatients, 72.5%) than among cALL (four of 10 patients, 40%) while this trend was not apparent in the adult group (30 and printing tests, and therefore tests with higher sensitivity were not required. In two patients (A23 and C9) insufficient material 47.5%, respectively). The predominant pre-B population among children and their higher incidence of relapse could was available for cloning. explain the higher (50%) than normally expected (25-30%) ence of MRD even at a level of 1:10 4 is still associated with impending relapse. All patients who were positive at 4-6 or 7-rate of relapse among children in our study.
12 months, relapsed. Conversely, negative PCR tests strongly correlated with persisting remission, as seven of nine patients tested negative at 1 or 2-3 months remain in remission to MRD time-points analysis date, although two patients relapsed at 35 and 39 months from presentation. Analysis was performed by grouping the assays to represent, approximately, periods of 1 month, 2-3 months, 4-6 months Third, the presence of MRD at the end of treatment (22-25 months) and outcome was analysed. Of three patients positive and 7-12 months from presentation. Tests performed at more than 12 months from presentation were too widely dispersed (C2, C10, C11) two have relapsed. Of three who tested negative, one patient (C15) relapsed at 35 months. to be meaningfully. For patients with more than one sample in a time period, the sample furthest from presentation was taken as representative and used in the analysis. The analysis was performed using the statistical program Minitab 10
Predictive value of positive and negative tests in children: Finally, the predictive value (PV) of a test (expressed by the (Microsoft window) to calculate the P value using a 2 test. accuracy of a positive test to predict relapse or of a negative test to predict continuous remission) was measured at different times. The value of a positive test, improved with time Results throughout the first 12 months, from 71 to 100% as progressively positive tests only occur in relapse patients (71.5% of MRD in patients with newly diagnosed ALL followed for у24 months or until relapse seven tested at 1 month -80% of five tested at 2-3 months -100% of three and of two tested at 4-6 and 7-12 months, respectively). The accuracy of negative tests to predict for con-A summary of all tests is illustrated in Figure 1 for childhood ALL and in Figure 2 for adult ALL. An example of fingertinued remission was lower (100% -77% -75% -80%) at the same time-points. printing analysis on two patients is illustrated in Figure 3 .
Children Adults
The number of patients positive for MRD at specific timeThe number of patients positive for MRD (irrespective of outcome) declined during the first 12 months from seven of points declined during the first 12 months from four (40%) of 10 at 1 month, to two (18%) of 11 between 7 and 12 months 11 (63.5%) at 1 month to two of seven (28.5%) at 12 months. Five of 14 patients (35.5%) at 2-3 months, and three of 11 ( Figure 2 ). Eight (61.5%) of 13 patients and five (33%) of 15 patients were positive for MRD at 2-3 months and 4-patients (27%) at 4-6 months were positive for MRD. Several types of analysis were applied to evaluate the prognostic value 6 months, respectively. All MRD tests were positive at у1:5 × 10 3 except for three patients at 4-6 months (A20, A21 of positive and negative MRD tests.
First, we analysed the occurrence of positive tests at individand A25) who had MRD detectable only at levels of 1:10 4 ( Figure 2 ). ual time-points in the remission and relapse groups, separately. This analysis showed that the proportion of positive tests First, we analysed the occurrence of positive tests at individual time-points in the remission and relapse groups, separwas markedly lower among patients who remained in remission compared with those who relapsed (Figure 4a ). This ately. A difference between the two clinical subgroups was apparent and statistically significant (P Ͻ 0.01) only at 4-difference was statistically significant throughout the period of observation (P Ͻ 0.03). At 1 month, two (33%) of six patients 6 months. At 1 month two (33%) of six patients in the remission group and two (50%) of four patients in the relapse were MRD positive in the remission group. However, all five patients (100%) who later relapsed were positive at 1 month group were positive for MRD (Figure 4b) . Similarly, at 2-3 months, MRD was detected in three (43%) of seven patients (P = 0.02). Only one (12.5%) of eight patients was found positive at 2-3 months in the remission group while four (66%) of in the remission group and in five (83.5%) of six patients in the relapse group. At 4-6 months one (10%) of 10 patients in six patients were positive in the relapse group (P = 0.03). None of the seven patients tested at 4-6 months and none of five the remission group was MRD positive compared to four (80%) of five patients in the relapse group (P Ͻ 0.01). All three patients tested at 7-12 months in the remission group was found MRD positive. By contrast, three (60%) of five patients patients positive at 4-6 months, who later relapsed, were posiand two of three patients were positive at 4-6 (P = 0.02) and 7-12 months, respectively, in the relapse group. . At 7-12 months, them (C10, A2-A29), samples prior to the relapse were MRD positive, and therefore we have no reason to suspect a change only one (14%) of seven patients in the remission group was positive. Only four patients were tested at 7-12 months in the of clonality at the time of relapse. However, in four patients, who had negative MRD tests 3, 12, 12 and 17 months prior relapse group and one of them was MRD positive (Figure 2) . Second, we analysed the ability of a positive test and the to their relapse, clonal change to explain the negative tests could not be ruled out. level of MRD to predict future relapse. The level of residual disease was found to be a relatively poor prognostic indicator of future relapse in adults, particularly up to 4 months postinduction. We observed that four patients were positive at Discussion 1 month (A8, A9, A22 and A28) and eight were positive at 3 months (A7, A10, A11, A21, A22, A27, A29 and A30). All MRD resolution in adult and childhood ALL 12 patients had MRD у1:5 × 10 3 (fingerprinting positive) but only six relapsed (A21, A22, A27-A30) while three patients
The results presented in this paper indicate that newly diagnosed ALL patients destined to relapse show a higher proremain in remission. Negative MRD was also a poor indicator of continuing remission, as we observed that five patients who portion of positive tests than in the remission group, irrespective of age and time of testing. Among patients in remission, later relapsed had negative MRD tests 3, 12, 12, 17 and 4.5 months, respectively, prior to their relapse (A23, A24, the proportion of positive tests decreased with time. At least two of six children and two of six adults in the remission A26, A19 and A30, Figure 2) . In two other patients who had tested negative during the first 5 months, a reappearance of group, showed MRD у1:5 × 10 3 at 1 month. These data are remarkably similar to previous studies in childhood ALL. Bri-MRD occurred between 5 and 10 months prior to the hematological relapse (A20 and A25, Figure 2 ). These two patients sco et al 4 reported MRD detectable in 50% of children between 34 and 45 days, with MRD at у10 3 strongly correlathad been tested at 3-4 month intervals, while the other four negative patients had only been tested once in their period of ing with subsequent relapse. These investigators also found that a larger proportion of adult patients showed a higher level follow-up. In one more patient (A23) a negative test was obtained 3 months prior to hematological relapse. This patient of MRD at 1 month than children, the highest level correlating with ultimate relapse. 18 We have now observed that persisthad undergone BMT 9 months earlier.
ence of MRD beyond 1 month appears to be a prognostic indicator of outcome, particularly in children. Only children destined to relapse were still positive beyond 2-3 months (with Predictive value (PV) of positive and negative tests in adult patients:
Relapse occurred in two of four patients with a the exception of one patient) in our study. By contrast, 43% of seven adults tested at 2-3 months were still positive. The positive test in the first month (PV positive, 50%). The PV of a negative test was also lower at 1 month (four of six negative persistence of MRD in remission adult ALL patients, compared to children suggests a more rapid resolution of residual disease patients, 66%). At 2-3 months, five of eight patients positive for MRD relapsed (PV positive 62.5%) but four of five negative in children in response to induction chemotherapy and might be consistent with the higher incidence of relapse among patients remained in remission (PV negative 80%), showing a better correlation of a negative test with remission than a posiadults. 29 tive test with relapse at this time-point. For tests carried out at later dates, a good correlation between a positive test and relapse and negative tests and remission was observed, partiSequential MRD analysis cularly at 4-6 months (80 and 90%). Overall, our data indicates that PV improves from 4-6 months while relatively little Many studies have demonstrated the technical feasibility of detecting MRD but there is a discrepancy as to the prognostic information is provided by tests carried out during the first 3 months post-induction in adults. This is in marked contrast significance of this finding. Our study suggests that analysis of sequential BM specimens provides useful information with to the results of MRD tests in children (see above).
regard to the monitoring of MRD. We found that a single test at 1 month might not be a sufficient indicator of future relapse as MRD is detected in у40% of patients, irrespective of age MRD analysis in post-relapse patients and outcome. In addition, if a cumbersome estimate of MRD 2,14,15,30,31 is to be avoided (providing that a sensitivity of Five children and three adults presented in first or subsequent relapse ( Figure 5 ).In addition, four children (C11, C14, C15 1:10 4 is obtained) serial sampling might help in identifying patients at increased risk of future relapse. Testing between and C16) and one adult (A25) who presented as newly diagnosed ALL, were tested following their first relapse. MRD approximately 3 and 4 months in children and beyond 4-6 months in adults would appear to be particularly informative analysis was carried out on BM specimens obtained following reinduction treatment or BMT ( Table 2) . Irrespective of age, for predicting outcome. In addition, our results suggest that in adults, conversion from negative to positive MRD during the MRD was detected in a higher proportion of patients analysed post-relapse compared to newly diagnosed remission first 6-9 months identifies poor-risk patients compared with those who have persistent negative MRD up to the end of patients in the same age group during the first 12 months post-reinduction.
treatment. The present results suggest that BM biopsies at 4-monthly intervals would be most useful for assessment of Overall, 16 patients were analysed at the time of relapse (11 children and five adults). In all patients, the B cell clone at relapse was identical to the clone (or one of the clones, in the case of oligoclonal B cell cases) detected at presentation.
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Figure 2
MRD in adult ALL patients. Abbreviations and key code
In seven adults and one child, no material was available at are as in Figure 1 . In addition, ‫,ء‬ the up to date clinical status is the time of relapse for comparison. All eight patients had a unknown beyond the time of follow-up indicated in this study. The key code for level of MRD assessed is given in Figure 1. monoclonal B cell proliferation at presentation. In four of MRD. They also show that cumbersome estimates of residual Level of sensitivity required in MRD tests disease 2, 14, 15, 30, 31 can be replaced by analysis of sequential With regard to the level of sensitivity required for MRD analysamples using a semiquantitative technique. sis, our data suggest that a level of detection of up to 1:10 4 appears to carry a strong predictive value. The use of ASO allowed MRD detection in at least four of our patients who Cytogenetic data were negative by FR1 tests and subsequently relapsed. In addition, if used for samples negative by FR1 fingerprinting, Cytogenetic analysis showed a great heterogeneity in chromoit adds a valid semiquantitative estimate of residual disease. somal abnormalities detected among the patients in the two A higher sensitivity, with or without accurate quantification, age groups. All patients with t(9;22) relapsed, confirming the would be of little predictive value. association of this abnormality with poor prognosis. By conFrom the technical point of view, we have found that FR1 trast, we noted that all three patients with t(1;19) (two children and one adult) are in first clinical remission. However, the any correlation with the clinical outcome, at the present time. in our present and previous studies. showing that the clone persists despite intensive chemoLeuk Lymphoma 1993; 2: 49-58.
therapy.
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